Our data suggest that low 53BP1 expression may predispose pancreatic tumor cells to become more vulnerable to changes of intrinsic metabolic stress, tumor microenvironment, and genotoxic stress from DNA damage based therapy. The gene discussed is TP53BP1; the disease is neoplasm.